RU2012138368A - 15-валентная вакцинная композиция на основе конъюгата пневмококкового полисахарида с белком - Google Patents
15-валентная вакцинная композиция на основе конъюгата пневмококкового полисахарида с белком Download PDFInfo
- Publication number
- RU2012138368A RU2012138368A RU2012138368/15A RU2012138368A RU2012138368A RU 2012138368 A RU2012138368 A RU 2012138368A RU 2012138368/15 A RU2012138368/15 A RU 2012138368/15A RU 2012138368 A RU2012138368 A RU 2012138368A RU 2012138368 A RU2012138368 A RU 2012138368A
- Authority
- RU
- Russia
- Prior art keywords
- immunogenic composition
- adjuvant
- aluminum
- crm
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 21
- 229960005486 vaccine Drugs 0.000 title 1
- 230000002163 immunogen Effects 0.000 claims abstract 18
- 239000002671 adjuvant Substances 0.000 claims abstract 14
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract 8
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims abstract 8
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract 7
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract 6
- 229910052782 aluminium Inorganic materials 0.000 claims abstract 6
- 150000004676 glycans Chemical class 0.000 claims abstract 6
- 229920001282 polysaccharide Polymers 0.000 claims abstract 6
- 239000005017 polysaccharide Substances 0.000 claims abstract 6
- 150000001720 carbohydrates Chemical class 0.000 claims abstract 4
- 229960002885 histidine Drugs 0.000 claims abstract 4
- 239000011780 sodium chloride Substances 0.000 claims abstract 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 230000028993 immune response Effects 0.000 claims abstract 2
- 230000001939 inductive effect Effects 0.000 claims abstract 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 201000005010 Streptococcus pneumonia Diseases 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Иммуногенная композиция, содержащая:(1) поливалентную смесь конъюгатов полисахаридов с белком, состоящую из капсульных полисахаридов серотипов 1, 3, 4, 5, 6A, 6B, 7F, 9V14, 18C, 19A, 19F, 22F, 23F и 33F, конъюгированных с белком-носителем; и(2) фармацевтически приемлемый носитель.2. Иммуногенная композиция по п.1, где белком-носителем является CRM.3. Иммуногенная композиция по п.1, дополнительно содержащая адъювант.4. Иммуногенная композиция по п.2, где адъювантом является адъювант на основе алюминия.5. Иммуногенная композиция по п.4, где адъювант выбран из группы, состоящей из фосфата алюминия, сульфата алюминия и гидроксида алюминия.6. Иммуногенная композиция по п.5, где адъювантом является фосфат алюминия.7. Иммуногенная композиция по п.1, составленная в форме однократной 0,5 мл дозы, содержащей 2 мкг каждого сахарида, за исключением 4 мкг для 6B; приблизительно 32 мкгбелка-носителяCRM; 0,125 мг адъюванта элементарного алюминия (0,5 мг фосфата алюминия); 150 мМ хлорида натрия и 20 мМ L-гистидинового буфера.8. Способ индуцирования иммунного ответа на капсульный полисахарид, включающий введение человеку иммунологически эффективного количества иммуногенной композиции по п.1.9. Способ по п.8, где иммуногенную композицию вводят в виде однократной 0,5 мл дозы, составленной таким образом, что она содержит 2 мкг каждого сахарида, за исключением 4 мкг для 6B; приблизительно 32 мкг белка-носителя CRM; 0,125 мг адъюванта элементарного алюминия (0,5 мг фосфата алюминия); 150 мМ хлорида натрия и 20 мМ L-гистидинового буфера.
Claims (9)
1. Иммуногенная композиция, содержащая:
(1) поливалентную смесь конъюгатов полисахаридов с белком, состоящую из капсульных полисахаридов серотипов 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F и 33F Streptococcus pneumonia, конъюгированных с белком-носителем; и
(2) фармацевтически приемлемый носитель.
2. Иммуногенная композиция по п.1, где белком-носителем является CRM197.
3. Иммуногенная композиция по п.1, дополнительно содержащая адъювант.
4. Иммуногенная композиция по п.2, где адъювантом является адъювант на основе алюминия.
5. Иммуногенная композиция по п.4, где адъювант выбран из группы, состоящей из фосфата алюминия, сульфата алюминия и гидроксида алюминия.
6. Иммуногенная композиция по п.5, где адъювантом является фосфат алюминия.
7. Иммуногенная композиция по п.1, составленная в форме однократной 0,5 мл дозы, содержащей 2 мкг каждого сахарида, за исключением 4 мкг для 6B; приблизительно 32 мкг белка-носителя CRM197; 0,125 мг адъюванта элементарного алюминия (0,5 мг фосфата алюминия); 150 мМ хлорида натрия и 20 мМ L-гистидинового буфера.
8. Способ индуцирования иммунного ответа на капсульный полисахарид Streptococcus pneumoniae, включающий введение человеку иммунологически эффективного количества иммуногенной композиции по п.1.
9. Способ по п.8, где иммуногенную композицию вводят в виде однократной 0,5 мл дозы, составленной таким образом, что она содержит 2 мкг каждого сахарида, за исключением 4 мкг для 6B; приблизительно 32 мкг белка-носителя CRM197; 0,125 мг адъюванта элементарного алюминия (0,5 мг фосфата алюминия); 150 мМ хлорида натрия и 20 мМ L-гистидинового буфера.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30272610P | 2010-02-09 | 2010-02-09 | |
| US61/302,726 | 2010-02-09 | ||
| PCT/US2011/023526 WO2011100151A1 (en) | 2010-02-09 | 2011-02-03 | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012138368A true RU2012138368A (ru) | 2014-03-20 |
Family
ID=44353903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012138368/15A RU2012138368A (ru) | 2010-02-09 | 2011-02-03 | 15-валентная вакцинная композиция на основе конъюгата пневмококкового полисахарида с белком |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8192746B2 (ru) |
| EP (1) | EP2533805A4 (ru) |
| JP (2) | JP2013518891A (ru) |
| KR (1) | KR101538535B1 (ru) |
| CN (1) | CN102858365A (ru) |
| AR (2) | AR080122A1 (ru) |
| AU (1) | AU2011216095B2 (ru) |
| BR (1) | BR112012019757B8 (ru) |
| CA (1) | CA2788680C (ru) |
| CL (1) | CL2012002195A1 (ru) |
| EC (1) | ECSP12012100A (ru) |
| IL (1) | IL221283A0 (ru) |
| MA (1) | MA34051B1 (ru) |
| MX (1) | MX2012009206A (ru) |
| MY (1) | MY159984A (ru) |
| NZ (1) | NZ601711A (ru) |
| PE (1) | PE20121698A1 (ru) |
| PH (1) | PH12012501559A1 (ru) |
| RU (1) | RU2012138368A (ru) |
| SG (2) | SG183199A1 (ru) |
| TN (1) | TN2012000377A1 (ru) |
| TW (1) | TW201136603A (ru) |
| UA (1) | UA106115C2 (ru) |
| WO (1) | WO2011100151A1 (ru) |
| ZA (1) | ZA201205737B (ru) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2789546C2 (ru) * | 2017-02-24 | 2023-02-06 | МЕРК ШАРП И ДОУМ ЭлЭлСи | Состав пневмококковой конъюгатной вакцины |
| US12280107B2 (en) | 2017-02-24 | 2025-04-22 | Merck Sharp & Dohme Llc | Pneumococcal conjugate vaccine formulations |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2425853A1 (en) | 2005-04-08 | 2012-03-07 | Wyeth LLC | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition |
| LT2351578T (lt) * | 2005-06-27 | 2017-04-10 | Glaxosmithkline Biologicals S.A. | Vakcinų gavimo būdas |
| EA015964B1 (ru) * | 2006-09-07 | 2012-01-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина |
| ES2969952T3 (es) | 2011-04-22 | 2024-05-23 | Wyeth Llc | Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos |
| EP2782594B1 (en) * | 2011-11-23 | 2019-04-17 | Merck Sharp & Dohme Corp. | Method for preparation of aluminum hydroxyphosphate adjuvant |
| KR102057217B1 (ko) * | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| US20140193451A1 (en) * | 2012-10-17 | 2014-07-10 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| KR20140075201A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| CN103495161B (zh) * | 2013-10-08 | 2019-06-18 | 江苏康泰生物医学技术有限公司 | 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法 |
| TWI586363B (zh) * | 2013-10-30 | 2017-06-11 | Sk化學公司 | 多價肺炎球菌多醣－蛋白質共軛物組成物 |
| KR20210032013A (ko) | 2014-01-21 | 2021-03-23 | 화이자 인코포레이티드 | 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체 |
| US12616744B2 (en) | 2014-01-21 | 2026-05-05 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| SI3096783T1 (sl) * | 2014-01-21 | 2021-09-30 | Pfizer Inc. | Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| PT3096785T (pt) * | 2014-01-21 | 2020-10-13 | Pfizer | Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas |
| CA2939416A1 (en) * | 2014-02-14 | 2015-08-20 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
| CN103893751B (zh) * | 2014-03-26 | 2016-04-20 | 天津康希诺生物技术有限公司 | 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法 |
| CA2988366C (en) * | 2015-06-08 | 2021-12-07 | Serum Institute Of India Private Ltd. | Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof. |
| DK3313436T3 (da) * | 2015-06-23 | 2021-03-08 | Biological E Ltd | Multivalent pneumokok-konjugatvaccine |
| KR102225282B1 (ko) * | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| US10159728B2 (en) * | 2015-09-10 | 2018-12-25 | Inventprise, Llc | Multivalent VLP conjugates |
| EP3436061A4 (en) * | 2016-03-31 | 2019-12-04 | Liffey Biotech Limited | Saccharide-polypeptide-conjugate compositions and methods of use thereof |
| EP3481407A4 (en) * | 2016-07-08 | 2020-04-01 | Hawaii Biotech, Inc. | West nile virus vaccine and method of use thereof |
| SG11201900794PA (en) | 2016-08-05 | 2019-02-27 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| TWI770044B (zh) | 2016-08-05 | 2022-07-11 | 南韓商Ｓｋ生物科技股份有限公司 | 多價肺炎球菌多醣-蛋白質共軛物組成物(一) |
| PH12019500672B1 (en) * | 2016-09-30 | 2024-02-23 | Biological E Ltd | Multivalent pneumococcal vaccine compositions comprising polysachharide-protein conjugates |
| KR102083973B1 (ko) * | 2016-10-28 | 2020-04-23 | 주식회사 엘지화학 | 향상된 IgG 역가를 갖는 다가면역원성 조성물 및 이의 용도 |
| MX2019007910A (es) | 2016-12-30 | 2019-12-05 | Sutrovax Inc | Conjugados de polipeptido-antigeno con aminoacidos no naturales. |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| KR20240169144A (ko) * | 2017-01-31 | 2024-12-02 | 머크 샤프 앤드 돔 엘엘씨 | 다당류-단백질 접합체 제조 방법 |
| US20200222550A1 (en) | 2017-01-31 | 2020-07-16 | Merck Sharp & Dohme Corp. | Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f |
| WO2018144799A1 (en) | 2017-02-03 | 2018-08-09 | SCHADECK, Eva, Barbara | Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof |
| WO2018156465A1 (en) * | 2017-02-24 | 2018-08-30 | Merck Sharp & Dohme Corp. | Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier |
| US11400162B2 (en) | 2017-02-24 | 2022-08-02 | Merck Sharp & Dohme Llc | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein |
| KR20190121330A (ko) | 2017-02-24 | 2019-10-25 | 머크 샤프 앤드 돔 코포레이션 | 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체의 면역원성의 증진 |
| KR20240018698A (ko) * | 2017-06-10 | 2024-02-13 | 인벤트프라이즈 인크. | 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| US20200360500A1 (en) * | 2017-08-16 | 2020-11-19 | Merck Sharp & Dohme Corp. | Pneumococcal conjugate vaccine formulations |
| US11389540B2 (en) | 2017-09-07 | 2022-07-19 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| CA3074706A1 (en) * | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| BR112020004509A8 (pt) * | 2017-09-07 | 2023-01-31 | Merck Sharp & Dohme | Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado |
| AU2018328040B2 (en) | 2017-09-07 | 2025-01-16 | Merck Sharp & Dohme Llc | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein |
| US11524076B2 (en) | 2017-09-07 | 2022-12-13 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| WO2019050813A1 (en) * | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER |
| EP3691677A4 (en) | 2017-10-04 | 2021-07-07 | Pogona, Llc | COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE |
| BR112020011414B8 (pt) | 2017-12-06 | 2023-01-31 | Merck Sharp & Dohme | Composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae |
| KR20230008923A (ko) * | 2018-02-05 | 2023-01-16 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균성 다당류-단백질 접합체 조성물 |
| BR112020014978A2 (pt) * | 2018-02-05 | 2020-12-22 | Sanofi Pasteur, Inc. | Composição de conjugado polissacarídeo-proteína pneumocócico multivalente |
| EP3782642A4 (en) | 2018-04-18 | 2022-04-13 | SK Bioscience Co., Ltd. | CAPSULE POLYSACCHARIDES FROM STREPTOCOCCUS PNEUMONIAE AND CONJUGATES THEREOF |
| US20210252125A1 (en) | 2018-04-30 | 2021-08-19 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates |
| JP7397000B2 (ja) | 2018-04-30 | 2023-12-12 | メルク・シャープ・アンド・ドーム・エルエルシー | 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法 |
| US12144855B2 (en) | 2018-04-30 | 2024-11-19 | Merck Sharp & Dohme Llc | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
| WO2019220304A1 (en) * | 2018-05-14 | 2019-11-21 | Tergene Biotech Pvt. Ltd. | 15 valent pneumococcal polysaccharide conjugate vaccine |
| US11389519B2 (en) | 2018-06-11 | 2022-07-19 | Inventprise, Llc | Virus-like particle conjugates |
| WO2020009462A1 (ko) * | 2018-07-06 | 2020-01-09 | 주식회사 유바이오로직스 | 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 폐렴구균에 의한 질환 예방 백신 |
| US12018134B2 (en) | 2018-07-19 | 2024-06-25 | Glaxosmithkline Biological Sa | Processes for preparing dried polysaccharides |
| IL281204B2 (en) * | 2018-09-12 | 2025-07-01 | Affinivax Inc | Multivalent pneumococcal vaccines |
| WO2020075201A1 (en) | 2018-10-12 | 2020-04-16 | Biological E Limited | Multivalent pneumococcal polysaccharide-protein conjugate vaccine |
| EP3897705A2 (en) | 2018-12-19 | 2021-10-27 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| CN114025790A (zh) * | 2019-06-05 | 2022-02-08 | 默沙东公司 | 免疫原性血清型35b肺炎球菌多糖-蛋白缀合物和用于制备其的缀合方法 |
| CN114025784A (zh) * | 2019-06-05 | 2022-02-08 | 默沙东公司 | 用针对肺炎链球菌血清型29进行保护的免疫原性组合物治疗患者的方法 |
| AU2020315673B2 (en) * | 2019-07-18 | 2025-01-23 | Celltrion, Inc. | Immunogenic composition comprising multivalent Streptococcus pneumoniae polysaccharide-protein conjugates |
| PH12022550110A1 (en) | 2019-07-31 | 2022-12-12 | Sk Bioscience Co Ltd | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
| WO2021255690A2 (en) | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| EP4192499A4 (en) | 2020-08-10 | 2024-09-25 | Inventprise, Inc. | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
| KR20220102871A (ko) * | 2021-01-14 | 2022-07-21 | (주)셀트리온 | 다가 폐렴구균 다당류-단백질 접합체를 포함하는 면역원성 조성물 |
| TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
| GEAP202616883A (en) | 2023-05-18 | 2026-03-25 | Merck Sharp & Dohme Llc | Compounds and adjuvant formulations useful in pneumococcal vaccines |
| TW202532099A (zh) | 2024-02-14 | 2025-08-16 | 美商默沙東有限責任公司 | 肺炎鏈球菌結合物疫苗及其使用方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2059693C (en) * | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
| DK1296715T4 (en) * | 2000-06-29 | 2016-03-07 | Smithkline Beecham Biolog | Multivalent vaccine composition. |
| GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| WO2005120563A2 (en) * | 2004-06-04 | 2005-12-22 | Pharmexa Inc. | Induction of an immune response against streptococcus pneumoniae polysaccharides |
| CN1660881A (zh) * | 2005-01-12 | 2005-08-31 | 北京万赛生物医药技术发展有限公司 | 新型的免疫刺激分子及其制备方法 |
| EP2425853A1 (en) * | 2005-04-08 | 2012-03-07 | Wyeth LLC | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition |
| LT2351578T (lt) * | 2005-06-27 | 2017-04-10 | Glaxosmithkline Biologicals S.A. | Vakcinų gavimo būdas |
| US20090035326A1 (en) * | 2005-11-01 | 2009-02-05 | Novartis Ag | Compositions with antigens adsorbed to calcium phosphate |
| BRPI0620460B8 (pt) * | 2005-12-22 | 2021-05-25 | Glaxosmithkline Biologicals Sa | uso de composição imunogênica para bebês, e, processo para produzir uma vacina |
| WO2007071786A2 (en) * | 2005-12-23 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Conjugate vaccines |
| WO2007127668A2 (en) * | 2006-04-26 | 2007-11-08 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| DK2129693T3 (en) * | 2007-03-23 | 2017-02-13 | Wyeth Llc | BRIEF PURIFICATION PROCEDURE FOR THE PREPARATION OF STREPTOCOCCUS PNEUMONIAE-Capsule POLYACCHARIDES |
| BRPI0813644B8 (pt) * | 2007-06-26 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina |
| CN101590224A (zh) | 2009-06-30 | 2009-12-02 | 广州精达医学科技有限公司 | 高效14价肺炎球菌结合疫苗 |
-
2011
- 2011-02-01 TW TW100104042A patent/TW201136603A/zh unknown
- 2011-02-03 BR BR112012019757A patent/BR112012019757B8/pt active IP Right Grant
- 2011-02-03 US US13/020,402 patent/US8192746B2/en active Active
- 2011-02-03 KR KR1020127020833A patent/KR101538535B1/ko active Active
- 2011-02-03 MY MYPI2012003537A patent/MY159984A/en unknown
- 2011-02-03 RU RU2012138368/15A patent/RU2012138368A/ru not_active Application Discontinuation
- 2011-02-03 JP JP2012552069A patent/JP2013518891A/ja not_active Ceased
- 2011-02-03 AU AU2011216095A patent/AU2011216095B2/en active Active
- 2011-02-03 EP EP20110742633 patent/EP2533805A4/en not_active Withdrawn
- 2011-02-03 AR ARP110100362A patent/AR080122A1/es unknown
- 2011-02-03 SG SG2012058236A patent/SG183199A1/en unknown
- 2011-02-03 NZ NZ601711A patent/NZ601711A/en unknown
- 2011-02-03 PE PE2012001178A patent/PE20121698A1/es not_active Application Discontinuation
- 2011-02-03 CA CA2788680A patent/CA2788680C/en active Active
- 2011-02-03 WO PCT/US2011/023526 patent/WO2011100151A1/en not_active Ceased
- 2011-02-03 CN CN2011800087423A patent/CN102858365A/zh active Pending
- 2011-02-03 MX MX2012009206A patent/MX2012009206A/es active IP Right Grant
- 2011-02-03 US US13/577,810 patent/US20120301502A1/en not_active Abandoned
- 2011-02-03 UA UAA201210582A patent/UA106115C2/ru unknown
- 2011-02-03 SG SG10201500350PA patent/SG10201500350PA/en unknown
- 2011-02-03 MA MA35187A patent/MA34051B1/fr unknown
- 2011-02-03 PH PH1/2012/501559A patent/PH12012501559A1/en unknown
-
2012
- 2012-07-24 TN TNP2012000377A patent/TN2012000377A1/en unknown
- 2012-07-30 ZA ZA2012/05737A patent/ZA201205737B/en unknown
- 2012-08-02 IL IL221283A patent/IL221283A0/en unknown
- 2012-08-07 CL CL2012002195A patent/CL2012002195A1/es unknown
- 2012-08-09 EC ECSP12012100 patent/ECSP12012100A/es unknown
-
2013
- 2013-09-13 JP JP2013189954A patent/JP2014012720A/ja active Pending
-
2019
- 2019-08-30 AR ARP190102473A patent/AR116043A2/es not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2789546C2 (ru) * | 2017-02-24 | 2023-02-06 | МЕРК ШАРП И ДОУМ ЭлЭлСи | Состав пневмококковой конъюгатной вакцины |
| US12280107B2 (en) | 2017-02-24 | 2025-04-22 | Merck Sharp & Dohme Llc | Pneumococcal conjugate vaccine formulations |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015100140A (ru) | Поливалентная композиция, содержащая конъюгаты пневмококковый полисахарид-белок | |
| RU2015121771A (ru) | Мультивалентная композиция на основе конъюгатов пневмококковый полисахарид-белок | |
| IL276230B2 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| HRP20120278T1 (hr) | Polivalentni pripravak konjugata pneumokoknog polisaharida s proteinom | |
| RU2015106791A (ru) | Иммуногенные композиции | |
| ZA201901170B (en) | Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates | |
| JP2020533438A5 (ru) | ||
| FI3585803T3 (fi) | Pneumokokkikonjugaattirokotteen formulaatioita | |
| JP2019526621A5 (ru) | ||
| IL276229B2 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| JP2005508849A5 (ru) | ||
| NZ601711A (en) | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition | |
| JP2012072157A5 (ru) | ||
| JP2008535838A5 (ru) | ||
| MX336934B (es) | Composicion conjugada polisacarido-proteina neumococica multivalente. | |
| PH12015501269A1 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| AR066376A1 (es) | Vacuna | |
| JP2019526620A5 (ru) | ||
| RU2022110368A (ru) | Иммуногенные композиции, содержащие конъюгированные капсульные сахаридные антигены, и их применение | |
| TH128171A (th) | องค์ประกอบวัคซีนคอนจูเกต 15-วาเลนท์ นิวโมคอคคอล โพลีแซคคาไรด์-โปรตีน | |
| TH96131B (th) | องค์ประกอบวัคซีนคอนจูเกต 15-วาเลนท์ นิวโมคอคคอล โพลีแซคคาไรด์-โปรตีน | |
| TH171459A (th) | องค์ประกอบมัลติวาเลนท์ นิวโมคอกคัสโพลีแซคคาไรด์-โปรตีน คอนจูเกต | |
| TH74129B (th) | สารผสมมัลติวาเลนท์นิวโมคอกคอลโพลีแซคคาไรด์-โปรตีนคอนจูเกต | |
| TH108545A (th) | สารผสมมัลติวาเลนท์นิวโมคอกคอลโพลีแซคคาไรด์-โปรตีนคอนจูเกต | |
| ZA202402956B (en) | Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150907 |